Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
Commentary|Videos|October 10, 2025

Integrating AI Across Legacy Clinical Trial Systems

Gain perspective on how agentic AI can bridge eCOA, EDC, IRT, and CTMS platforms to reduce manual effort and improve operational efficiency.

In a recent video interview with Applied Clinical Trials, Michelle Longmire, MD, co-founder and CEO of Medable, discussed the role of agentic artificial intelligence (AI) in clinical trials. She highlighted that 45% of clinical development time is wasted due to delays and siloed data. Agentic AI aims to reduce this by leveraging technology in areas previously untouched, freeing up human resources for strategic work. The human-in-the-loop concept ensures that AI supports, rather than replaces, human decision-making. Integration of AI across legacy systems is facilitated by model context protocols, reducing manual effort. Automation handles routine tasks, while critical decisions remain human-controlled. No-code platforms for AI tools require clear job descriptions and validation similar to human training.

ACT: As clinical trials become more data-intensive and multi-platform, what are the biggest challenges to integrating AI systems across existing eCOA, EDC, IRT, and CTMS platforms? How should they be addressed?

Longmire: When I look at the first horizon of agentic AI and some of the value, it's actually to reduce the burden of legacy technology, and what I mean by that is today, a lot of the layering in of legacy technology has only meant more work for clinical operations experts and clinical drug developers, so agents are able to do work across these systems using MCP or model context protocols. Really, I think if there's a system that has been integrated before, MCPS bring leverage to those existing integrations and existing frameworks. So far, what I mean is, I think people often wonder, ‘Well, can I integrate this?’ I think the real question is, have you ever integrated it before, and if you have, then MCPs offer a whole new type of leverage to that problem. The operational aspects of working across systems is one of the ultimate and early value props for agentic AI. I really see that some of these first horizon value is just going to be, ‘Hey, now you know how to log into 50 different things and aggregate the data in a bunch of different places.’ You can use the agents to access those systems, retrieve critical data and provide critical insights, really reducing the manual effort of the current legacy technology environment.


Related to this article

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.